Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 15/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17516257 | 0.90 | ALDH1A1 (0.50) | ADRA1ACYP3A4CYP2C19ALDH1A1MEN1 | |
| SCHEMBL18251701 | 0.83 | CYP3A4 (0.52) | CYP3A4CYP2C19 | |
| SCHEMBL17152376 | 0.82 | DPP4 (0.46) | ADRA1ACYP3A4CYP2C19 | |
| SCHEMBL19658401 | 0.82 | ADRA1A (0.50) | ADRA1AALDH1A1LMNA | |
| SCHEMBL31482179 | 0.82 | ADRA1A (0.50) | ADRA1AALDH1A1LMNA | |
| SCHEMBL12396446 | 0.82 | CYP3A4 (0.55) | CYP3A4CYP2C19ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL18145297 | 0.81 | ALDH1A1 (0.51) | ADRA1AALDH1A1LMNA | |
| SCHEMBL18267300 | 0.80 | ALDH1A1 (0.58) | CYP3A4CYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL25604665 | 0.80 | ALDH1A1 (0.58) | CYP3A4CYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL478903 | 0.80 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | ADRA1A 1517/4885CYP3A4 4473/4885CYP2C19 4039/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | ADRA1A 1517/4885CYP3A4 4473/4885CYP2C19 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.